Ipratropiu/Salbutamol Cipla

Ipratropium bromide and Salbutamol, the active ingredient in Ipratropiu/Salbutamol Cipla, is a bronchodilator presented as an inhalation solution for inhalation use. It treats bronchospasm associated with chronic obstructive pulmonary disease (COPD) and asthma in adult patients. GNH USA supplies Ipratropiu/Salbutamol Cipla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ipratropium bromide and Salbutamol is a bronchodilator combination used in obstructive airway diseases.

- COPD: provides relief of bronchospasm and improves airflow in chronic obstructive pulmonary disease. - Asthma: reduces acute bronchoconstriction and supports symptom control in asthma. - Reversible airway obstruction: helps relieve bronchospasm in conditions such as chronic bronchitis or other reversible airway narrowing.

Adverse reactions may occur with inhalation therapy.

Common Side Effects: - Tremor: mild shaking, often of the hands. - Headache: transient discomfort. - Throat irritation: dryness or soreness. - Cough: occasional irritation during inhalation. - Palpitations: awareness of heartbeat. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Paradoxical bronchospasm: worsening airway constriction. - Cardiac arrhythmia: irregular heart rhythm. - Severe allergic reaction: rash, itching, swelling. - Angioedema: swelling of face, lips, or tongue. - Tachycardia: rapid heart rate. - Hypokalemia: low blood potassium levels.

Use with clinical caution and monitor patients for specific concerns.

- Cardiac status: assess for tachycardia or arrhythmias before initiating therapy. - Hypersensitivity: avoid in patients with known allergy to ipratropium, salbutamol, or formulation excipients. - Diabetes: monitor blood glucose as β2‑agonists may affect glycemic control. - Thyroid disease: use cautiously in hyperthyroid patients due to potential tachycardia. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Drug interaction potential requires attention to co‑administered agents.

Major Interactions (Avoid): - Beta‑blockers: may diminish bronchodilator effect. - MAO inhibitors: risk of hypertensive crisis. - Tricyclic antidepressants: can increase cardiovascular stimulation.

Moderate Interactions (Monitor Closely): - Diuretics: may exacerbate hypokalemia. - Theophylline: additive stimulant effect on the heart. - Corticosteroids: increased risk of oral thrush when used together. - Anticholinergic drugs: potential additive anticholinergic burden.